News + Filings Transactions Holdings
|
Cormorant Asset Management, LP
| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 03/16/2023 | Ambrx Biopharma Inc. | | Purchase | Ordinary Shares | 500k | $10.15 | $5.1M | See Footnotes | 03/14/2023 |
| 03/15/2023 | Ambrx Biopharma Inc. | | Purchase | Ordinary Shares | 250k | $10.60 | $2.6M | See Footnotes | 03/14/2023 |
| 03/14/2023 | Ambrx Biopharma Inc. | | Purchase | Ordinary Shares | 250k | $9.95 | $2.5M | See Footnotes | 03/14/2023 |
| 01/11/2022 | Vigil Neuroscience, Inc. | | Conversion | Common Stock | 616.8k | $0.00 | $0 | See Footnotes | 01/11/2022 |
| 01/11/2022 | Vigil Neuroscience, Inc. | | Conversion | Series B Convertible Preferred Stock | 616.8k | $0.00 | $0 | See Footnotes | 01/11/2022 |
| 10/25/2021 | Ventyx Biosciences, Inc. | | Conversion | Common Stock | 785.3k | $0.00 | $0 | See Footnotes | 10/25/2021 |
| 10/25/2021 | Ventyx Biosciences, Inc. | | Purchase | Common Stock | 625k | $16.00 | $10M | See Footnotes | 10/25/2021 |
| 10/25/2021 | Ventyx Biosciences, Inc. | | Conversion | Series A Convertible Preferred Stock | 548.3k | $0.00 | $0 | See Footnotes | 10/25/2021 |
| 10/25/2021 | Ventyx Biosciences, Inc. | | Conversion | Series B Convertible Preferred Stock | 237k | $0.00 | $0 | See Footnotes | 10/25/2021 |
| 10/13/2021 | Pyxis Oncology, Inc. | PYXS | Conversion | Common Stock | 668.9k | $0.00 | $0 | See Footnotes | 10/13/2021 |
| 10/13/2021 | Pyxis Oncology, Inc. | PYXS | Purchase | Common Stock | 450k | $16.00 | $7.2M | See Footnotes | 10/13/2021 |
| 10/13/2021 | Pyxis Oncology, Inc. | PYXS | Conversion | Series B Convertible Preferred Stock | 668.9k | $0.00 | $0 | See Footnotes | 10/13/2021 |
| 08/02/2021 | Icosavax, Inc. | ICVX | Conversion | Common Stock | 426.4k | $0.00 | $0 | See Footnotes | 08/02/2021 |
| 08/02/2021 | Icosavax, Inc. | ICVX | Conversion | Series B-1 Convertible Preferred Stock | 426.4k | $0.00 | $0 | See Footnotes | 08/02/2021 |
| 07/02/2021 | Aerovate Therapeutics, Inc. | AVTE | Conversion | Common Stock | 1.5M | $0.00 | $0 | See Footnotes | 07/02/2021 |
| 07/02/2021 | Aerovate Therapeutics, Inc. | AVTE | Purchase | Common Stock | 500k | $14.00 | $7M | See Footnotes | 07/02/2021 |
| 07/02/2021 | Aerovate Therapeutics, Inc. | AVTE | Conversion | Series A Convertible Preferred Stock | 1.5M | $0.00 | $0 | See Footnotes | 07/02/2021 |
| 06/29/2021 | Elevation Oncology, Inc. | ELEV | Conversion | Common Stock | 2M | $0.00 | $0 | See Footnotes | 06/29/2021 |
| 06/29/2021 | Elevation Oncology, Inc. | ELEV | Purchase | Common Stock | 250k | $16.00 | $4M | See Footnotes | 06/29/2021 |
| 06/29/2021 | Elevation Oncology, Inc. | ELEV | Conversion | Series B Convertible Preferred Stock | 2M | $0.00 | $0 | See Footnotes | 06/29/2021 |
| 06/21/2021 | Verve Therapeutics, Inc. | | Conversion | Common Stock | 709.2k | $0.00 | $0 | See Footnotes | 06/21/2021 |
| 06/21/2021 | Verve Therapeutics, Inc. | | Purchase | Common Stock | 275k | $19.00 | $5.2M | See Footnotes | 06/21/2021 |
| 06/21/2021 | Verve Therapeutics, Inc. | | Conversion | Series B Convertible Preferred Stock | 709.2k | $0.00 | $0 | See Footnotes | 06/21/2021 |
| 04/15/2021 | Biomea Fusion, Inc. | | Grant | Stock Option (right to buy) | 28.9k | $17.00 | $491.5k | | 04/15/2021 |
| 03/30/2021 | Design Therapeutics, Inc. | DSGN | Purchase | Common Stock | 750k | $20.00 | $15M | See Footnotes | 03/30/2021 |
| 03/30/2021 | Design Therapeutics, Inc. | DSGN | Conversion | Common Stock | 4.4M | $0.00 | $0 | See Footnotes | 03/30/2021 |
| 03/30/2021 | Design Therapeutics, Inc. | DSGN | Conversion | Series B Convertible Preferred Stock | 1.4M | $0.00 | $0 | See Footnotes | 03/30/2021 |
| 03/30/2021 | Design Therapeutics, Inc. | DSGN | Conversion | Series A Convertible Preferred Stock | 3M | $0.00 | $0 | See Footnotes | 03/30/2021 |
| 03/16/2021 | Prometheus Biosciences, Inc. | RXDX | Conversion | Common Stock | 1.8M | $0.00 | $0 | See Footnotes | 03/16/2021 |
| 03/16/2021 | Prometheus Biosciences, Inc. | RXDX | Purchase | Common Stock | 375k | $19.00 | $7.1M | See Footnotes | 03/16/2021 |
| 03/16/2021 | Prometheus Biosciences, Inc. | RXDX | Conversion | Series D-1 Convertible Preferred Stock | 763.3k | $0.00 | $0 | See Footnotes | 03/16/2021 |
| 03/16/2021 | Prometheus Biosciences, Inc. | RXDX | Conversion | Series D-2 Convertible Preferred Stock | 1.1M | $0.00 | $0 | See Footnotes | 03/16/2021 |
| 12/18/2020 | BioAtla, Inc. | | Conversion | Common Stock | 1.5M | $0.00 | $0 | See Footnotes | 12/18/2020 |
| 12/18/2020 | BioAtla, Inc. | | Purchase | Common Stock | 800k | $18.00 | $14.4M | See Footnotes | 12/18/2020 |
| 12/18/2020 | BioAtla, Inc. | | Conversion | Series D Convertible Preferred Stock | 1.5M | $0.00 | $0 | See Footnotes | 12/18/2020 |
|
|